Join
Live feed
·
INSIDERFilingvia Quantisnow
Dyne Therapeutics Inc. logo

Chief Financial Officer Lucera Erick sold $26,585 worth of shares (1,448 units at $18.36) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 123,925 units (SEC Form 4) to cover taxes

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DYN (Dyne Therapeutics Inc.) and more on Quantisnow.